{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T15:59:50Z","timestamp":1794844790771,"version":"4.9.1"},"reference-count":33,"publisher":"BMJ","issue":"2","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Eur J Hosp Pharm"],"accepted":{"date-parts":[[2023,12,5]]},"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1136\/ejhpharm-2023-003779","type":"journal-article","created":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T00:43:40Z","timestamp":1704847420000},"page":"178-185","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":16,"title":["Switching anti-CGRP monoclonal antibodies in chronic migraine: real-world observations of erenumab, fremanezumab and galcanezumab"],"prefix":"10.1136","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4720-1972","authenticated-orcid":false,"given":"Jamie","family":"Talbot","sequence":"first","affiliation":[{"name":"Department of Neurology, Derriford Hospital, Plymouth, UK"},{"name":"University of Birmingham, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Stuckey","sequence":"additional","affiliation":[{"name":"Department of Neurology, Derriford Hospital, Plymouth, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha","family":"Wood","sequence":"additional","affiliation":[{"name":"Department of Neurology, Derriford Hospital, Plymouth, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Gordon","sequence":"additional","affiliation":[{"name":"Torbay Hospital, Torquay, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ginette","family":"Crossingham","sequence":"additional","affiliation":[{"name":"Department of Neurology, Derriford Hospital, Plymouth, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"Weatherby","sequence":"additional","affiliation":[{"name":"Department of Neurology, Derriford Hospital, Plymouth, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,1,5]]},"reference":[{"key":"2025090703241738000_32.2.178.1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102418759786"},{"key":"2025090703241738000_32.2.178.2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.4853"},{"key":"2025090703241738000_32.2.178.3","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1001\/jamaneurol.2018.1212","article-title":"Evaluation of Galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trial","volume":"75","author":"Stauffer","year":"2018","journal-title":"JAMA Neurol"},{"key":"2025090703241738000_32.2.178.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709038"},{"key":"2025090703241738000_32.2.178.5","doi-asserted-by":"crossref","first-page":"e2211","DOI":"10.1212\/WNL.0000000000006640","article-title":"Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study","volume":"91","author":"Detke","year":"2018","journal-title":"Neurology"},{"key":"2025090703241738000_32.2.178.6","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30083-2"},{"key":"2025090703241738000_32.2.178.7","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(15)00249-5"},{"key":"2025090703241738000_32.2.178.8","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1212\/WNL.0000000000002801","article-title":"TEV-48125 for the preventive treatment of chronic migraine: efficacy at early time points","volume":"87","author":"Bigal","year":"2016","journal-title":"Neurology"},{"key":"2025090703241738000_32.2.178.9","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1177\/0333102420946725","article-title":"Real-world effectiveness and tolerability of Erenumab: a retrospective cohort study","volume":"40","author":"Kanaan","year":"2020","journal-title":"Cephalalgia"},{"key":"2025090703241738000_32.2.178.10","doi-asserted-by":"crossref","unstructured":"Lambru G , Hill B , Murphy M , et al . A prospective real-world analysis of Erenumab in refractory chronic migraine. J Headache Pain 2020;21. doi:10.1186\/s10194-020-01127-0","DOI":"10.1186\/s10194-020-01127-0"},{"key":"2025090703241738000_32.2.178.11","doi-asserted-by":"crossref","DOI":"10.1186\/s10194-021-01247-1","article-title":"Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study)","volume":"22","author":"Vernieri","year":"2021","journal-title":"J Headache Pain"},{"key":"2025090703241738000_32.2.178.12","doi-asserted-by":"crossref","unstructured":"Cohen JM , Thompson S , Patterson-Lomba O , et al . Real-world reductions in migraine and headache days for patients with chronic and episodic migraine initiating Fremanezumab in the US (4171). Neurology 2021;96.(15_supplement) doi:10.1212\/WNL.96.15_supplement.4171","DOI":"10.1212\/WNL.96.15_supplement.4171"},{"key":"2025090703241738000_32.2.178.13","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s40120-021-00245-4","article-title":"Real-world treatment profiles, clinical outcomes, and Healthcare resource utilization of patients with migraine prescribed Erenumab: A multicenter chart-review study of US headache centers","volume":"10","author":"Faust","year":"2021","journal-title":"Neurol Ther"},{"key":"2025090703241738000_32.2.178.14","doi-asserted-by":"crossref","DOI":"10.1186\/s12883-021-02123-w","article-title":"Long-term safety and tolerability of Eptinezumab in patients with chronic migraine: a 2-year, open-label, phase 3 trial","volume":"21","author":"Kudrow","year":"2021","journal-title":"BMC Neurol"},{"key":"2025090703241738000_32.2.178.15","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s10194-020-01214-2","article-title":"Improvements in pain, medication use and quality of life in onabotulinumtoxinA-resistant chronic migraine patients following Erenumab treatment\u2013real world outcomes","volume":"22","author":"Talbot","year":"2021","journal-title":"J Headache Pain"},{"key":"2025090703241738000_32.2.178.16","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-021-00834-9"},{"key":"2025090703241738000_32.2.178.17","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1080\/01616412.2021.1940672","article-title":"Network meta-analysis on efficacy and safety of different anti-CGRP Monoclonal antibody regimens for prophylaxis and treatment of episodic migraine","volume":"43","author":"Shi","year":"2021","journal-title":"Neurol Res"},{"key":"2025090703241738000_32.2.178.18","doi-asserted-by":"publisher","DOI":"10.1177\/03331024211053571"},{"key":"2025090703241738000_32.2.178.19","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.nrleng.2020.10.008","article-title":"Failure of Monoclonal antibodies against CGRP or its receptor does not imply lack of efficacy of other drugs from the same class","volume":"36","author":"Porta-Etessam","year":"2021","journal-title":"Neurolog\u00eda (English Edition)"},{"key":"2025090703241738000_32.2.178.20","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/head.13729","article-title":"Non-responders to treatment with antibodies to the CGRP-receptor may profit from a switch of antibody class","volume":"60","author":"Ziegeler","year":"2020","journal-title":"Headache"},{"key":"2025090703241738000_32.2.178.21","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1177\/03331024211048765","article-title":"Effect of antibody switch in non-responders to a CGRP receptor antibody treatment in migraine: A multi-center retrospective cohort study","volume":"42","author":"Overeem","year":"2022","journal-title":"Cephalalgia"},{"key":"2025090703241738000_32.2.178.22","unstructured":"Robbins L . CGRP Monoclonal Antibodies for Chronic Migraine: Year 1 of Clinical Use. 2019."},{"key":"2025090703241738000_32.2.178.23","doi-asserted-by":"crossref","DOI":"10.1136\/ejhpharm-2021-002946","article-title":"Switching of Monoclonal antibodies against calcitonin gene-related peptide in chronic migraine in clinical practice: a case series","volume":"30","author":"Brice\u00f1o-Casado","year":"2023","journal-title":"Eur J Hosp Pharm"},{"key":"2025090703241738000_32.2.178.24","doi-asserted-by":"crossref","DOI":"10.1136\/jnnp-2022-ABN.384","article-title":"059 switching CGRP Monoclonal antibodies for chronic migraine: real-world outcomes of 37 episodes","volume":"93","author":"Weatherall","year":"2022","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2025090703241738000_32.2.178.25","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2023.1154420","article-title":"Effect of switching to Erenumab in non-responders to a CGRP ligand antibody treatment in migraine: A real-world cohort study","volume":"14","author":"Overeem","year":"2023","journal-title":"Front Neurol"},{"key":"2025090703241738000_32.2.178.26","doi-asserted-by":"crossref","DOI":"10.1186\/s10194-023-01552-x","article-title":"Clinical evaluation of super-responders vs. non-responders to CGRP(-Receptor) Monoclonal antibodies: a real-world experience","volume":"24","author":"Raffaelli","year":"2023","journal-title":"J Headache Pain"},{"key":"2025090703241738000_32.2.178.27","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1111\/ene.15816","article-title":"Patterns of response to anti-calcitonin gene-related peptide Monoclonal antibodies during first 6 months of treatment in resistant migraine patients: impact on outcome","volume":"30","author":"Torres-Ferrus","year":"2023","journal-title":"Eur J Neurol"},{"key":"2025090703241738000_32.2.178.28","doi-asserted-by":"publisher","DOI":"10.1177\/0333102417738202"},{"key":"2025090703241738000_32.2.178.29","doi-asserted-by":"publisher","DOI":"10.1023\/A:1026119331193"},{"key":"2025090703241738000_32.2.178.30","doi-asserted-by":"publisher","DOI":"10.1111\/anae.12148"},{"key":"2025090703241738000_32.2.178.31","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1212\/WNL.0000000000207292","article-title":"Late response to anti-CGRP Monoclonal antibodies in migraine: A multicenter, prospective, observational study","volume":"101","author":"Barbanti","year":"2023","journal-title":"Neurology"},{"key":"2025090703241738000_32.2.178.32","doi-asserted-by":"publisher","DOI":"10.1111\/head.13428"},{"key":"2025090703241738000_32.2.178.33","doi-asserted-by":"publisher","DOI":"10.1177\/1740774515602688"}],"container-title":["European Journal of Hospital Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ejhpharm-2023-003779","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T10:24:27Z","timestamp":1757240667000},"score":1,"resource":{"primary":{"URL":"https:\/\/ejhp.bmj.com\/lookup\/doi\/10.1136\/ejhpharm-2023-003779"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,5]]},"references-count":33,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,2,21]]},"published-print":{"date-parts":[[2025,3]]}},"alternative-id":["10.1136\/ejhpharm-2023-003779"],"URL":"https:\/\/doi.org\/10.1136\/ejhpharm-2023-003779","relation":{},"ISSN":["2047-9956","2047-9964"],"issn-type":[{"value":"2047-9956","type":"print"},{"value":"2047-9964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,5]]}}}